



Laur-Alexandru Botos¹ and Manoja Rasamanikkam² ¹CELL GUIDANCE SYSTEMS, Cambridge, UK ²BMG LABTECH, Aylesbury, UK

- Detects different expression levels of exosome markers
- Simple assay offering a high degree of reproducibility
- Highly sensitive and specific: only antigens displayed in multiple copies are detectable

Introduction

Exosomes are extracellular vesicles (EVs) of endosomal origin. These vesicles contain proteins, lipids and nucleic acids and facilitate intercellular communication between different cell types within an organism. The rapidly expanding EV research field benefits tremendously from tools for the detection of exosomes and their content. Tetraspanin proteins such as CD9, CD63 and CD81 with exposed domains are particularly enriched in the exosome membrane and are often used as exosome biomarkers. These tetraspanins show a distinct pattern of prevalence on exosomes in different cell types. The Time Resolved Immunoflourescence (TRIFic™) exosome developed specifically for analyzing the levels of these tetraspanin proteins on the surface of exosomes.

TRIFicTM exosome detection kits enable researchers to directly measure tetraspanins present on exosomes from sources such as cell culture media, urine or blood with low background signals and high sensitivity. Using a very sensitive Time-Resolved Fluorescence (TRF) plate reader ensures optimal assay performance. The kit has been evaluated on the FLUOstar Omega, CLARIOstar *Plus* and the PHERAstar *FSX* with all instruments meeting the sensitivity requirements for the kit.



Assay Principle

Fig. 1: Principle of the Time Resolved Immunoflourescence $[\mbox{TRIFic}^{\rm TM}]$ exosome detection assay.

Step 1: Biotinylated antibody is bound to streptavidin coated assay plates. The kit provides a 96-well microplate with an 8-well strip format.

Step 2: Biological samples are added. Exosomes and any free antigen are captured by the antibody.

Step 3: Europium [Eu]-labelled antibody [identical to antibody used in Step 1] is added and binds specifically to target exosome antigen. The epitopes of any bound monomers are already occupied and not detected. Samples are then read on a Time-Resolved Fluorescence [TRF] plate reader such as the PHERAstar FSX.

Materials & Methods

- TRIFic™ Exosome Detection Kit (Cell Guidance Systems)
- Exo-spin[™] Exosome Purification Kit (Cell Guidance Systems)
- Streptavidin coated 96-well microplate (incl. in kit by Cell Guidance Systems)
- TRF microplate reader PHERAstar FSX (BMG LABTECH)

Exosome Sample Preparation

25 µg of exosomes were purified from conditioned cell culture media using the Exo-spin™ exosome purification kit. The protein amount was determined by Bradford assay. Serial dilutions in PBS by a factor of 0.5 were prepared from 100 µg/ml to 0.8 µg/ml, obtaining a total of 8 different exosome concentrations.

TRIFic™ protocol

100 µl of freshly diluted biotin-conjugated antibody (2 ng/µl) was added to each well of the streptavidin coated plate. Subsequently, incubation and washes using the protocol described below were performed. 100 µl of each exosome dilution (prepared by serial dilution as described above) was transferred to each well. 100 µl of PBS was used as blank. Samples were incubated and washed again as described below. 100 µl of freshly diluted Eu-labeled antibody (0.25 ng/µl) was then added to each well of the streptavidin coated plate. Samples were incubated and washed again as described below. 100 µl of Europium Fluorescence Intensifier solution was then added to each well. The plate was incubated for 15 min at room temperature (RT) on a plate shaker at 750 RPM. TRF was then measured using a TRF compatible microplate reader (PHERAstar FSX).

Incubation and wash protocol

The plate was incubated for 1 hour at RT on a plate shaker at 750 RPM. Each plate was washed three times using 250 μl wash buffer for each wash cycle. The remaining wash buffer was removed.



Instrument settings		
Optic settings	Time resolved fluorescence (TRF)	
	Filters	Excitation: 337 nm Emission: 615 nm
General settings	Number of flashes	200 with flash lamp
	Settling time	0.3 s
	Integration start	200 µs
	Integration time	400 µs

Results & Discussion

Exo-spinTM isolated exosome samples from conditioned cell culture media were analyzed using the TRIFicTM assay. The expression of CD9, CD63 and CD81 (commonly used surface exosome markers), were measured on exosomes derived from two different cancer cell lines. The data below was obtained using the PHERAstar *FSX*, however all three BMG LABTECH instruments exceeded the required performance criteria for the assay.



Fig. 2: Marker detection on exosomes from prostate cancer cells using TRIFic™. Each datapoint represents an average (N=3).



Fig. 3: Marker detection on exosomes from colorectal cancer cells using TRIFic™. Each datapoint represents an average (N=2).

The error bars for each datapoint in Fig. 2 and Fig. 3 show a very small variance in signal, unnoticeable for some data points. This demonstrates the great consistency and reproducibility offered together by the TRIFic™ kit and PHERAstar FSX. Moreover, the R^2 values for every serial dilution show excellent linearity, this is consistent with the data for total protein concentration.



Fig. 4: Signal to blank ratio of CD81 detection on exosomes from prostate cancer cells. To obtain the datapoints average values were used (N=3).



Fig. 5: Signal to blank ratio of CD63 detection on exosomes from colorectal cancer cells. To obtain the datapoints average values were used [N=2].

The data presented on Fig. 4 and Fig. 5 further demonstrates the consistency of the TRF signal generated by the assay over a wide intensity range.

Conclusion

The TRIFic[™] assay has been used successfully, together with the BMG LABTECH plate readers. They obtained accurate and reliable TRF signal for different exosome markers. The great linearity and consistency of the signal over a wide range of exosome concentrations demonstrates the robustness of the assay to generate useful data points over a wide dynamic range. This highly sensitive assay can also be used with unpurified samples.

References

- Marina Colombo *et al.* Annu. Rev. Cell Dev. Biol. (2014) 30:255-89. DOI: 10.1146/annurev-cellbio-101512-122326
- 2. Diedrik Duijvesz *et al.* Int. J. Cancer (2015) **137**: 2869-78. DOI: 10.1002/ijc.29664
- 3. <u>www.cellgs.com</u>

